Vertex Pharmaceuticals | VRTX - Eigenkapital Und Reserven

Aktienkurs
423.17
Täglich Wechseln
-6.97 -1.62%
Monatlich
-4.51%
Jährlich
-16.94%
Q2 Prognose
421.08




Eigenkapital Und Reserven Veränderung Datum
AbbVie USD -3.27B 628M 2025-12
Acadia Pharmaceuticals USD 917.27M 94.89M 2025-09
Agios Pharmaceuticals USD 1.11B 84M 2026-03
Alnylam Pharmaceuticals USD 789.18M 555.28M 2025-12
Amgen USD 8.66B 961M 2025-12
Arrowhead Research USD 568.42M 102.37M 2025-12
Biogen USD 18.65B 394.9M 2026-03
BioMarin Pharmaceutical USD 6.09B 30.29M 2025-12
Bristol-Myers Squibb USD 18.55B 1.06B 2025-09
Gilead Sciences USD 22.62B 1.16B 2025-12
Incyte USD 5.62B 455.37M 2026-03
Insmed USD 738.98M 206.6M 2025-12
Ionis Pharmaceuticals USD 491.41M 2.32M 2026-03
J&J USD 81.19B 358M 2026-03
Merck USD 51.85B 2.79B 2025-09
Moderna USD 8.65B 680M 2025-12
Neurocrine Biosciences USD 3.25B 249.5M 2025-12
Novartis USD 46.13B 1.38B 2025-12
Pfizer USD 92.8B 4.11B 2025-09
PTC Therapeutics USD -205.31M 49.56M 2025-12
Puma Biotechnology USD 115.27M 10.55M 2025-09
Regeneron Pharmaceuticals USD 31.42B 166.7M 2026-03
Roche Holding CHF 33.8B 758M 2025-12
Sangamo BioSciences USD 19.6M 14.7M 2025-06
Sanofi EUR 72.81B 1.1B 2026-03
Sarepta Therapeutics USD 1.14B 179.5M 2025-12
Ultragenyx Pharmaceutical USD 9.16M 142.13M 2025-09
United Therapeutics USD 7.1B 506M 2025-12
Vertex Pharmaceuticals USD 18.67B 1.35B 2025-12